All dollar amounts reflected in Canadian dollars unless otherwise stated

VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended June 30, 2025 (“Q2 2025” ), and provided an update on recent corporate developments.

Q2 2025 Financial Highlights

Reported a net loss of $2,916,944 .

Research and development (R&D) expenses were $1,611,985 , reflecting continued advancement of AI-powered drug candidates.

General and administrative (G&A) expenses were $1,213,489 including investor & public relations and exchange-related fees.

Operating expens

See Full Page